These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29993150)

  • 1. Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity: The Daily Chemotherapy Toxicity self-Assessment Questionnaire.
    Maguire R; Kotronoulas G; Donnan PT; Paterson C; McCann L; Connaghan J; Di Domenico DGG; Kearney N
    Eur J Cancer Care (Engl); 2018 Nov; 27(6):e12890. PubMed ID: 29993150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric assessment of the Chinese version of the MASCC Antiemesis Tool (MAT) for measuring chemotherapy-induced nausea and vomiting.
    Tan JY; Suen LK; Molassiotis A
    Support Care Cancer; 2016 Sep; 24(9):3729-37. PubMed ID: 27039204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The development of a new QOL Questionnaire on chemotherapy - induced emesis and vomiting--investigation of reliability and validity. Group for Investigation of QOL Questionnaire for Anti-Emetics Used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative study].
    Ishihara Y; Nukariya N; Kobayashi K; Yoneda S; Matsuda T; Yakushiji M; Yamakido M; Fukuoka M; Niitani H; Furue H
    Gan To Kagaku Ryoho; 1996 May; 23(6):745-55. PubMed ID: 8645026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology.
    Anderson RT; Keating KN; Doll HA; Camacho F
    Oncologist; 2015 Jul; 20(7):831-8. PubMed ID: 26084809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.
    Matsuda Y; Okita K; Furuhata T; Kutomi G; Yamashita K; Sato Y; Takimoto R; Hirata K
    Support Care Cancer; 2015 Nov; 23(11):3331-9. PubMed ID: 26003425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translation and psychometric assessment of the Persian version of the Rhodes Index of Nausea, Vomiting and Retching (INVR) scale for the assessment of chemotherapy-induced nausea and vomiting.
    Moradian S; Shahidsales S; Ghavam Nasiri MR; Pilling M; Molassiotis A; Walshe C
    Eur J Cancer Care (Engl); 2014 Nov; 23(6):811-8. PubMed ID: 24661358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The assessment and management of chemotherapy-related toxicities in patients with breast cancer, colorectal cancer, and Hodgkin's and non-Hodgkin's lymphomas: A scoping review.
    Fox P; Darley A; Furlong E; Miaskowski C; Patiraki E; Armes J; Ream E; Papadopoulou C; McCann L; Kearney N; Maguire R
    Eur J Oncol Nurs; 2017 Feb; 26():63-82. PubMed ID: 28069154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
    Di Maio M; Gallo C; Leighl NB; Piccirillo MC; Daniele G; Nuzzo F; Gridelli C; Gebbia V; Ciardiello F; De Placido S; Ceribelli A; Favaretto AG; de Matteis A; Feld R; Butts C; Bryce J; Signoriello S; Morabito A; Rocco G; Perrone F
    J Clin Oncol; 2015 Mar; 33(8):910-5. PubMed ID: 25624439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.
    Keefe DM; Elting LS; Nguyen HT; Grunberg SM; Aprile G; Bonaventura A; Selva-Nayagam S; Barsevick A; Koczwara B; Sonis ST
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):675-80. PubMed ID: 25055935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and testing of the patient-reported chemotherapy indicators of symptoms and experience: patient-reported outcome and process indicators sensitive to the quality of nursing care in ambulatory chemotherapy settings.
    Armes J; Wagland R; Finnegan-John J; Richardson A; Corner J; Griffiths P
    Cancer Nurs; 2014; 37(3):E52-60. PubMed ID: 24141376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring chemotherapy-induced nausea and emesis.
    Martin CG; Rubenstein EB; Elting LS; Kim YJ; Osoba D
    Cancer; 2003 Aug; 98(3):645-55. PubMed ID: 12879484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer.
    Williams SA; Schreier AM
    Oncol Nurs Forum; 2004; 31(1):E16-23. PubMed ID: 14722602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
    Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
    Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?
    Macquart-Moulin G; Viens P; Palangié T; Bouscary ML; Delozier T; Roché H; Janvier M; Fabbro M; Moatti JP
    J Clin Oncol; 2000 Feb; 18(4):754-64. PubMed ID: 10673516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity.
    Zachariae R; Paulsen K; Mehlsen M; Jensen AB; Johansson A; von der Maase H
    Psychother Psychosom; 2007; 76(6):376-84. PubMed ID: 17917474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of fatigue in and care needs of Turkish women with breast cancer.
    Can G; Durna Z; Aydiner A
    Cancer Nurs; 2004; 27(2):153-61. PubMed ID: 15253173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.
    Basch E; Jia X; Heller G; Barz A; Sit L; Fruscione M; Appawu M; Iasonos A; Atkinson T; Goldfarb S; Culkin A; Kris MG; Schrag D
    J Natl Cancer Inst; 2009 Dec; 101(23):1624-32. PubMed ID: 19920223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Leuven questionnaire for Patient Self-care during Chemotherapy (L-PaSC): instrument development and psychometric evaluation.
    Coolbrandt A; Van den Heede K; Clemens K; Milisen K; Laenen A; Wildiers H; Verslype C
    Eur J Oncol Nurs; 2013 Jun; 17(3):275-83. PubMed ID: 22901548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.